scholarly journals Unusual presentation of Kaposi sarcoma in an HIV-negative woman

2020 ◽  
Vol 26 (4) ◽  
Author(s):  
Allison L Limmer ◽  
Katherine E Park ◽  
Anisha B Patel ◽  
Auris O Huen
2021 ◽  
Vol 85 (3) ◽  
pp. AB156
Author(s):  
Connor Stonesifer ◽  
Megan Trager ◽  
Alexandra Coromilas ◽  
Mark Strom ◽  
Dawn Queen

2018 ◽  
Vol 13 (1) ◽  
Author(s):  
Nader Kim El-Mallawany ◽  
Jimmy Villiera ◽  
William Kamiyango ◽  
Erin C. Peckham-Gregory ◽  
Michael E. Scheurer ◽  
...  

Author(s):  
Aline Fernanda Cruz ◽  
José Augusto Dias Araújo ◽  
Samuel Macedo Costa ◽  
Júlio César Tanos De Lacerda ◽  
Patrícia Carlos Caldeira ◽  
...  

AIDS ◽  
2019 ◽  
Vol 33 (7) ◽  
pp. 1263-1264 ◽  
Author(s):  
Alessandra Latini ◽  
Lavinia Alei ◽  
Renato Covello ◽  
Antonio Cristaudo ◽  
Manuela Colafigli ◽  
...  

Author(s):  
Dimitris Kounatidis ◽  
Dimitra Rontogianni ◽  
Dimitrios Sampaziotis ◽  
Maria Vardaka ◽  
Chara Giatra ◽  
...  

Background: Multicentric Castleman Disease (MCD) presents with enlarged lymph nodes in multiple regions and systemic inflammatory symptoms, due to the dysregulation of cytokines, most commonly interleukin-6 (IL-6). Human herpes virus-8 (HHV-8) is strongly related to MCD (HHV-8-associated MCD) and is being implicated in cytokine dysregulation in patients, the majority of whom are HIV positive or immunosuppressed. Preferred treatment of HHV-8- associated MCD depends on the presence or not of concurrent Kaposi sarcoma and on whether the patient has life-threatening organ failure or poor performance status thought to be related to HHV- 8-associated MCD. Case Presentation: Herein, we describe a female patient with HHV-8 positive, HIV negative MCD, who responded well to the administration of rituximab once weekly for four weeks alone for three cycles. Conclusion: HHV-8 positive, HIV negative MCD treatment modalities are only anecdotal due to the rarity of this form of MCD. Administration of rituximab alone seems to be beneficial among patients with good performance status and the absence of life-threatening organ failure in cases of HHV-8 positive, HIV negative MCD.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4970-4970
Author(s):  
Anuradha Avinash Belur ◽  
Arun Kumar Arumugam Raajasekar ◽  
Srikant Nannapaneni ◽  
Thandavababu Chelliah

Abstract Case Description: - A 76 year old lady was diagnosed with Chronic Lymphocytic Leukemia (CLL) with 11 q deletion after she presented with generalized lymphadenopathy and anemia. She was treated with rituximab 375mg/m2 day1 and bendamustine 60mg/m2 on day 1 and day 2 and completed six cycles of treatment. After the sixth cycle she developed multiple itchy, papular lesions with bleeding on both lower extremities. She was evaluated multiple times by vascular surgery and dermatology without a definitive diagnosis. She underwent a biopsy with staining for HHV-8, CD31 and CD34 which was positive confirming the diagnosis of Kaposi sarcoma. ELISA test for HIV was negative. She was started on treatment with Doxorubicin 20 mg/m2every 3 weeks and with 3 cycles there was significant regression of the lesions. Discussion-: We describe a case of CLL which was initially started on treatment with rituximab and bendamustine. She tolerated the treatment well, but a few months later presented with skin lesions which on biopsy was diagnosed as Kaposi sarcoma. It is very uncommon for Kaposi sarcoma to develop in a HIV negative patient. This patient was immunocompromised with recent chemotherapy. Rituximab specifically depletes B cells and leads to impaired T cell mediated immunity. This case illustrates the importance of a high index of suspicion in patients treated with rituximab as it is used for a number of hematologic malignancies like leukemia, lymphoma as well as non-malignant conditions like autoimmune disorders. While infusion reactions and reactivation of hepatitis B are side effects physicians are aware of and cautious of while using rituximab, Kaposi’s Sarcoma remains a less known side effect. Awareness of this possibility is important in physicians prescribing rituximab. Footnotes * Asterisk with author names denotes non-ASH members. Disclosures No relevant conflicts of interest to declare.


Mycoses ◽  
2006 ◽  
Vol 49 (2) ◽  
pp. 152-154 ◽  
Author(s):  
Jason J. Sico ◽  
Eric Hughes
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document